Clinical Policy: Vorinostat (Zolinza)
Reference Number: CP.PHAR.83
Effective Date: 12.01.12
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Vorinostat (Zolinza®) is a histone deacetylase (HDAC) inhibitor.

FDA Approved Indication(s)
Zolinza is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Zolinza is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Cutaneous T-Cell Lymphoma (must meet all):
      1. Diagnosis of CTCL;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. Request meets one of the following (a or b):*
         a. Dose does not exceed 400 mg (4 capsules) per day;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN

   Approval duration:
   Medicaid/HIM – 6 months
   Commercial – Length of Benefit

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. Cutaneous T-Cell Lymphoma (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Zolinza for CTCL and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed 400 mg (4 capsules) per day;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 12 months
Commercial – Length of Benefit

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
CTCL: cutaneous T-cell lymphoma
FDA: Food and Drug Administration
HDAC: histone deacetylase
NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
None reported

Appendix D: World Health Organization-European Organization for Research and Treatment of Cancer, 2018 - Classification of CTCL*
- Mycosis fungoides (MF)
  - MF variants and subtypes
    - Folliculotropic MF
    - Pagetoid reticulosis
Granulomatous slack skin

- Sezary syndrome (SS)
- Adult T-cell leukemia/lymphoma (ATLL)
- Primary cutaneous CD30+ lymphoproliferative disorders
  - Cutaneous anaplastic large cell lymphoma (ALCL)
  - Lymphomatoid papulosis
- Subcutaneous panniculitis-like T-cell lymphoma
- Extramedullary NK**/T-cell lymphoma, nasal type
- Chronic active EBV infection
- Primary cutaneous peripheral T-cell lymphoma, rare subtypes
  - Primary cutaneous gamma-delta T-cell lymphoma
  - Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (CD8+ AECTCL)
  - Primary cutaneous CD4+ small/medium-sized T-cell lymphoproliferative disorder
  - Primary cutaneous acral CD8+ T-cell lymphoma
- Primary cutaneous peripheral T-cell lymphoma, NOS

*Non-Hodgkin’s lymphomas (NHLs) include lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, and natural killer cells. Cutaneous T-cell lymphomas (CTCLs) are a subset of NHLs characterized by skin involvement and the potential to progress to lymph nodes, blood, and visceral organs. Mycosis fungoides, the most common CTCL, is an extranodal NHL of mature T-cells with primary skin involvement. Sezary syndrome, a less common CTCL, is characterized by significant blood involvement and lymphadenopathy.

**Extranodal NK-cell lymphoma is considered a CTCL subtype under the policy criteria.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTCL</td>
<td>400 mg PO QD</td>
<td>400 mg/day</td>
</tr>
</tbody>
</table>

VI. Product Availability

Capsule: 100 mg

VII. References

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Converted policy to new template. Criteria: added adult age restriction; removed denial for hepatic impairment since not an absolute contraindication; removed dose adjustment criteria; added max dose restriction criteria; changed initial approval period to 3 months and continuation to 6; added requirement that CTCL cutaneous manifestations be present per PI. Limited appendices to abbreviation key; removed list of systemic therapies since not used to restrict criteria.</td>
<td>12.15</td>
<td>01.16</td>
</tr>
<tr>
<td>Policy converted to new template. Two appendices added – classification of CTCL and examples of CTCL systemic therapies. NCCN recommended uses added.</td>
<td>12.16</td>
<td>01.17</td>
</tr>
<tr>
<td>Updated references and added max dose and changed 3/6 approval duration to 6/12 month approval duration.</td>
<td>08.17.17</td>
<td>11.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: policies combined for Commercial and Medicaid lines of business; age and specialist requirements added; continuation of care statement added; NCCN and FDA-approved uses summarized for improved clarity (criteria limited to CTLC diagnosis); references reviewed and updated.</td>
<td>05.08.18</td>
<td>08.18</td>
</tr>
<tr>
<td>3Q 2019 annual review: HIM line of business added; no significant changes; references reviewed and updated.</td>
<td>05.14.19</td>
<td>08.19</td>
</tr>
<tr>
<td>3Q 2020 annual review: no significant changes; Appendix D subtype classification updated per NCCN/WHO-EORTC 2018; references reviewed and updated.</td>
<td>05.12.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,
contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2012 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.